BAYER AKTIENGESELLSCHAFT «12345...» Página 3 de 137 desde 01/07/1988 hasta 01/11/2024 30/07/2019 07:41 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Q2 2019 Analyst and Investor Briefing Número de registro: 280796 26/07/2019 13:29 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Not intended for U.S. and UK Media - Bayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in Europe Número de registro: 280659 22/07/2019 16:00 BAYER AKTIENGESELLSCHAFT Transmissions and purchases of capital undertakings Yellow Wood Partners to acquire iconic Dr. Scholl’s™ brand from Bayer Número de registro: 280415 19/07/2019 11:22 BAYER AKTIENGESELLSCHAFT Trading: admissions, changes and removals BAYER AG: VOLUNTARY DELISTING OF THE BAYER’S SHARES FROM THE MADRID AND BARCELONA STOCK EXCHANGES Número de registro: 280372 18/07/2019 13:09 BAYER AKTIENGESELLSCHAFT Strategic plans, profit forecasts and presentations Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancer Número de registro: 280294 16/07/2019 10:58 BAYER AKTIENGESELLSCHAFT Announcements of public presentations and meetings Bayer: Q2 2019 Publication Schedule Número de registro: 280227 11/07/2019 17:51 BAYER AKTIENGESELLSCHAFT Trading: admissions, changes and removals La sociedad rectora de la Bolsa de Valores de Madrid comunica la exclusión de negociación de las acciones de BAYER AKTIENGESELLSCHAFT. Número de registro: 280129 11/07/2019 13:43 BAYER AKTIENGESELLSCHAFT Trading: admissions, changes and removals La sociedad rectora de la bolsa de valores de Barcelona comunica la exclusión de negociación de las acciones de BAYER AKTIENGESELLSCHAFT. Número de registro: 280108 08/07/2019 15:15 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Not intended for U.S. and UK Media - Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolism Número de registro: 280015 02/07/2019 09:16 BAYER AKTIENGESELLSCHAFT Transmissions and purchases of capital undertakings LEO Pharma completes the acquisition of Bayer’s prescription dermatology business Número de registro: 279787 Página 3 de 137 «12345...»
